Williams K J, Bax R P, Brown H, Machin S J
ICI Pharmaceuticals, Mereside, Alderley Park, Macclesfield, Cheshire.
J Clin Pathol. 1991 Sep;44(9):738-41. doi: 10.1136/jcp.44.9.738.
The incidence and type of pathology causing a prolonged prothrombin time and clinical bleeding episodes were assessed in a multicentre study of 1109 patients receiving cefotetan, a N-methyl-thiotetrazole (NMTT), or equivalent antibiotics. There was no significant difference in the incidence of a prolonged prothrombin time (9.9% with cefotetan, 8.0% with comparable antibiotics) of clinical bleeding episodes. However, prothrombin time increases of greater than 12 seconds were significantly (p = 0.002) greater with cefotetan (3.8%) than with comparators (0.8%). In both antibiotic groups increases in prothrombin time were more likely following surgery and in patients who were older, with a high platelet count, low albumin, or higher urea and creatinine concentrations. All antibiotic treatment can be associated with prolonged prothrombin times and new agents should always be assessed in a large multicentre study before the practical, clinical importance of haemostatic defects can be defined.
在一项针对1109例接受头孢替坦（一种N-甲基硫代四唑（NMTT））或等效抗生素治疗的患者的多中心研究中，对导致凝血酶原时间延长和临床出血事件的病理发生率及类型进行了评估。凝血酶原时间延长的发生率（头孢替坦组为9.9%，可比抗生素组为8.0%）及临床出血事件发生率无显著差异。然而，头孢替坦组凝血酶原时间增加超过12秒的比例（3.8%）显著高于对照药物组（0.8%）（p = 0.002）。在两个抗生素组中，术后以及年龄较大、血小板计数高、白蛋白低或尿素和肌酐浓度较高的患者凝血酶原时间更易延长。所有抗生素治疗都可能与凝血酶原时间延长有关，在确定止血缺陷的实际临床重要性之前，新药物应始终在大型多中心研究中进行评估。
